突变型 z-bio 2025-07-03 3081

　　Shanghai, June 18, 2025 - Shanghai Alis Pharmaceutical Technology Co., Ltd. (stock code: 688578, hereinafter referred to as "Alis") announced that its latest approved innovative drug, Arika® (Gerreser citrate tablets) has successfully prescribed the first prescription in many places across the country. This marks the official implementation of Erika® clinical practice, providing a new treatment option for adult patients with KRAS G12C mutant advanced non-small cell lung cancer (NSCLC).

　　On June 16, Shanghai Alis Pharmaceutical Technology Co., Ltd. and Kelleying Pharmaceutical Group jointly held the departure ceremony of the first batch of commercial preparations of Alike® (Gallereser Citrate Tablets). At 10:18 am, a drug transport vehicle loaded with Alike® successfully set off from the Kelleying Pharmaceutical Tianjin factory and officially launched nationwide commercial supply.

　　On June 18, Arikai® quickly arrived at medical terminals in 15 provinces and cities across the country, including Shanghai, Beijing, Jiangsu, Zhejiang, etc., and prescribed first prescriptions in many hospitals in Beijing and Shanghai. The efficient implementation of resources from all parties fully demonstrates Alice's high attention and rapid response to patient needs.

　　On May 22, Arika® was approved for marketing by the National Drug Administration (NMPA) for use in adult patients with KRAS G12C mutant advanced non-small cell lung cancer (NSCLC) who have received at least one systematic treatment. This is another new lung cancer drug approved for sale by Eversha® (Vometinib methanesulfonate tablets). Thanks to the unique drug eutectic design and stable configuration, Arike® exhibits good efficacy and safety, with a low incidence of adverse events related to grade ≥3 treatment, and has good gastrointestinal safety characteristics. As the only drug among the approved KRAS G12C inhibitors in China that achieves single oral administration per day, Arika® not only provides a more efficient and convenient treatment plan, but also reshapes the treatment pattern of KRAS G12C mutant patients.

　　As more and more prescriptions are implemented in the future, data on the efficacy, safety and patient compliance of Irika® in the real world will continue to be improved. We look forward to the expansion of application boundaries in terms of indications, combined treatment strategies, etc., to help build a more complete KRAS G12C treatment system, and to bring good news to more patients.